Expressions and clinical significance of pAkt1 and hTERT in epithelial ovarian carcinoma

doi:10.3760/cma.j.issn.1673422X.2017.09.006

Abstract

Abstract: ObjectiveTo evaluate the expressions and prognostic significance of phosphorylation of protein kinase B1 (pAkt1) and human telomere reverse transcriptase (hTERT) in epithelial ovarian carcinoma. MethodsThe expressions of pAkt1 and hTERT were examined by immunohistochemical SP method in 72 cases of epithelial ovarian carcinoma and 10 normal endometrial tissues to analyze the correlation between pAkt1 and hTERT and their relationships with clinicpathological features and prognosis. ResultsThe positive expression rate of pAkt1 in epithelial ovarian carcinoma was 73.6%, and the positive expression rate of hTERT was 56.9%， compared with normal ovarian tissues, with statistical significance (χ2=20.814, P<0.001; χ2=11.389, P<0.001).The expression of pAkt1 was not associated with hTERT expression (r=0.075, P=0.532) in epithelial ovarian carcinoma. The expressions of pAkt1 and hTERT in epithelial ovarian carcinoma were correlated with tumor differentiation status (χ2=6.475, P=0.011; χ2=1.370, P=0.001). The diseasefree survival of patients with pAkt1 and hTERT positive coexpression was significantly shorter than others (8.585 months vs. 11.227 months, χ2=4.361, P=0.037), but there was no significant difference in overall survival (11.107 months∶11.695 months, χ2=0.394, P=0.530). ConclusionpAkt1 and hTERT are highly expressed in epithelial ovarian carcinoma, and high coexpression of pAkt1 and hTERT indicates poor prognosis in epithelial ovarian carcinoma.

Key words: Ovarian neoplasms, Phosphorylation of protein kinase B1, Human telomere reverse transcriptase

LIU Ze-Ye, HU Jing, FENG Yu-Huan. Expressions and clinical significance of pAkt1 and hTERT in epithelial ovarian carcinoma[J]. Journal of International Oncology, 2017, 44(8): 668-671.

References

［1］张海燕，孙红. Akt基因在上皮性卵巢癌组织中的表达及临床意义［J］. 现代妇产科进展, 2014, 23(12): 964967. DOI: 10.13283/j.cnki.xdfckjz.2014.12.013. ［2］ Ramlee MK, Wang J, Toh WX, et al. Transcription regulation of the human telomerase reverse transcriptase (hTERT) gene［J］. Genes (Basel), 2016, 7(8): E50. DOI: 10.3390/genes7080050. ［3］ Shay JW. Role of telomeres and telomerase in aging and cancer［J］. Cancer Discov, 2016, 6(6): 584593. DOI: 10.1158/21598290.CD160062. ［4］庄志明, 林天旗, 林建贵, 等. 靶向沉默Notch1基因对肾透明细胞癌增殖、凋亡及Akt/mTOR信号通路的影响［J］. 中华泌尿外科杂志, 2017, 38(2): 136140. DOI: 10.3760/cma.j.issn.10006702.2017.02.016. ［5］关长群, 吴秀娟, 普雄明, 等. 微RNA126介导磷脂酰肌醇3激酶调节亚基2及磷脂酰肌醇3激酶/蛋白激酶B信号与肿瘤关系的新进展［J］. 医学综述, 2016, 22(19): 37953797, 3798. DOI: 10.3969/j.issn.10062084.2016.19.014. ［6］ Verhaak RG, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of highgrade serous ovarian carcinoma［J］. J Clin Invest, 2013, 123(1): 517525. DOI: 10.1172/JCI65833. ［7］ GarciaDios DA, Lambrechts D, Coenegrachts L, et al. Highthroughput interrogation of PIK3CA, PTEN, KＲAS, FBXW7 and TP53 mutations in primary endometrial carcinoma［J］. Gynecol Oncol, 2013, 128(2): 327334. DOI: 10.1016/j.ygyno.2012.11.037. ［8］ Cohen MM Jr. The AKT genes and their roles in various disorders［J］. Am J Med Genet A, 2013, 161A(12): 29312937. DOI: 10.1002/ajmg.a.36101. ［9］ Avan A, Narayan R, Giovannetti E, et al. Role of Akt signaling in resistance to DNAtargeted therapy［J］. World J Clin Oncol, 2016, 7(5): 352369. ［10］ Jia W, Chang B, Sun L, et al. REDD1 and pAKT overexpression may predict poor prognosis in ovarian cancer［J］. Int J Clin Exp Pathol, 2014, 7(9): 59405949. ［11］ Rahman M, Nakayama K, Rahman MT. et al. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma［J］. Hum Pathol, 2012, 43(12): 21972206. DOI: 10.1016/j.humpath.2012.03.011. ［12］冯玉环, 易建平, 陈莹, 等. 磷酸化蛋白激酶B1和人端粒酶反转录酶在卵巢上皮性癌中的表达及其临床意义［J］. 肿瘤研究与临床, 2017, 29(6): 378381. DOI: 10.3760/cma.j.issn.10069801.2017.06.005. ［13］邹存华, 王宏, 宋冬冬, 等. P38MAPK信号通路与uPA在卵巢癌细胞及组织中表达的相关性［J］. 中国癌症杂志, 2015, (8): 572578. DOI: 10.3969/j.issn.10073969.2015.08.003. ［14］ Sasaki T, Kuniyasu H, Luo Y. et al. AKT activation and telomerase reverse transcriptase expression are concurrently associated with prognosis of gastric cancer［J］. Pathobiology, 2014, 81(1): 3641. DOI: 10.1159/000351721.

[1]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[2]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.
[3]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[4]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[5]	Li Chenxi, Zhao Hongwei. Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors [J]. Journal of International Oncology, 2021, 48(3): 180-183.
[6]	Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao. GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway [J]. Journal of International Oncology, 2021, 48(12): 716-722.
[7]	Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan. Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer [J]. Journal of International Oncology, 2021, 48(11): 660-665.
[8]	Yang Lifen, Song Wei, Xu Dawei, Wu Jun, Gao Ran. Mechanisms of miR-103a-3p/CHI3L1 in proliferation and vascular mimicry of ovarian cancer cells [J]. Journal of International Oncology, 2020, 47(6): 333-339.
[9]	Xue Chen, Zhao Yue, Shi Guang, Tang Yan. Research progress of PD-1/PD-L1 inhibitors in ovarian cancer [J]. Journal of International Oncology, 2020, 47(5): 312-315.
[10]	Yang Yiting, Cheng Zhongping. The role of inflammatory cytokines in chemoresistance of epithelial ovarian cancer [J]. Journal of International Oncology, 2020, 47(4): 249-251.
[11]	Fan Yangyang, Wang Ying, Yuan Feng, Du Shanping, He Rongrong, Jia Yan. Study on the mechanism of MALAT1 targeting miR-142-3p in ovarian cancer chemotherapy resistance [J]. Journal of International Oncology, 2020, 47(2): 82-89.
[12]	Quan Ruiquan, Zhang Li, Kuang Li, Li Hongbo, Xiao Meixian. Efficacy of olaparib combined with bevacizumab in the treatment of patients with recurrent platinum-sensitive ovarian cancer and its effect on serum HE4, CA125 and CTC levels [J]. Journal of International Oncology, 2020, 47(10): 606-610.
[13]	Tang Nanmin, Yu Zhancai. Transforming growth factor-β signaling pathway and targeted therapy in ovarian cancer [J]. Journal of International Oncology, 2019, 46(9): 562-565.
[14]	Chu Chaonan, Huang Qi. Comparison of the efficacy and safety of liposome doxorubicin and gemcitabine combined with oxaliplatin in the treatment of recurrent platinum resistant ovarian cancer [J]. Journal of International Oncology, 2019, 46(1): 32-35.
[15]	Yuan Qiuyue, Qiao Huimin, Zhang Shengmiao, Xia Baoguo, Bi Shuna, Chen Long. Research progress of circulating tumor DNA in ovrian cancer [J]. Journal of International Oncology, 2019, 46(1): 57-60.